Safety and Efficacy of Shi's Traumatology Osteopathic Manipulative Treatment for Cervicogenic Dizziness (SESTOMTCD)
Cervicogenic Dizziness
About this trial
This is an interventional treatment trial for Cervicogenic Dizziness focused on measuring Cervicogenic dizziness, Vertigo, Manipulation, Osteopathic manipulative treatment
Eligibility Criteria
Inclusion Criteria: 18~65 years old; Meet diagnostic criteria of cervicogenic dizziness; Had cervical odontoid process deviation showed ·on CT 3D reconstruction of cervical spine or CT plain scan of atlantoaxial joint cross-section at inclusion. Patients had dizziness symptom at inclusion 31 ≤ DHI ≤ 60; Course of disease ≥ 1 month; Patients were volunteer to joint this study, and signed written informed consent. Exclusion Criteria: Dizziness caused by other diseases (like otogenic, cerebral, traumatic, ophthalmogenic, neurofunctional, intracranial tumor, subclavian steal syndrome etc.) Cervical vertebra has fracture, dislocation, tuberculosis, acute cervical spine disc protrusion, infection, cancer; Patients has severe heart, liver, brain, kidney complications or other serious diseases; Uncontrolled hypertension grade Ⅱ or higher, or blood pressure≥160/100mmHg after antihypertensive treatment; Patients has a history of carotid plaque; Pregnancy, lactation, family planning, or patients judged not to use effective contraception. Patients has mental diseases; Has Suspected or confirmed history of alcohol or drug abuse Patients are afraid of Manual therapy Patients are allergic to betahistine mesylate tablets Had participated in other clinical trials within 3 months before screening Researchers considered Other conditions that were not appropriate to participate in the trial
Sites / Locations
- Yueyang traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese MedicineRecruiting
- Shanghai General HospitalRecruiting
- Baoshan traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Other
Manual therapy group
Merislon group
Patients receive Shi's traumatology osteopathic manipulative treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments.
Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to the control group, for 2 weeks, 6mg a day, three times a day.